-
Boehringer Ingelheim Acquires T3 Pharmaceuticals to Boost Immuno-Oncology Portfolio
•
Germany’s Boehringer Ingelheim has announced the purchase of Switzerland-based biotechnology firm T3 Pharmaceuticals this week, in a strategic move to expand its immuno-oncology pipeline. The transaction is valued at up to CHF 450 million (USD 510 million), highlighting Boehringer Ingelheim’s commitment to advancing cancer treatments. T3 Pharmaceuticals’ Innovative Approach to…
-
Bayer Halts Late-Stage Trial for Asundexian After Underperformance
•
Germany-headquartered Bayer (ETR: BAYN) announced the termination of a late-stage trial for its antithrombotic candidate asundexian. Asundexian, once considered a potential blockbuster, was outperformed by the standard of care in preventing stroke and systemic embolism in patients with atrial fibrillation, the most lucrative indication for the drug, with an estimated…
-
Venus Medtech Partners with Valgen Holding on DragonFly Valve System
•
China-based Venus Medtech (Hangzhou) Inc., (HKG: 2500), has entered into a strategic partnership with Valgen Holding Corporation concerning Valgen’s DragonFly transcatheter mitral valve clamp system (DF). The financial terms of the agreement have not been disclosed. Commercial Collaboration and Market ExpansionUpon obtaining market approval for the DragonFly system, the two…
-
Oculotronics Secures Pre-Series A Funding for Ophthalmic Surgical Robotics
•
Oculotronics, a Guangzhou-based developer of ophthalmic surgical robots, has reportedly raised tens of millions of renminbi in a pre-Series A financing round. The funds raised will be allocated towards the clinical study and industrialization of its flagship product, a micron-level high-precision ophthalmic surgical robot. Additionally, the capital will support the…
-
Sumitomo Pharma Receives Chinese Approval for Xenleta to Treat Pneumonia
•
Japan-based Sumitomo Pharma Co., Ltd (OTCMKTS: DNPUF) has secured market approval in China for Xenleta (lefamulin acetate), a drug indicated for the treatment of community-acquired pneumonia in adults. The approval was obtained through Sumitomo’s Suzhou-based subsidiary, which already has Mepem (meropenem), a carbapenem antibiotic, in its Chinese market portfolio, and…
-
Gilead Announces Low-Carbon Bronchodilator Study for H1 2024
•
Gilead Sciences Inc. (NASDAQ: GILD) has announced plans for a Phase III study in the first half of 2024 for a new iteration of its bronchodilator Ventolin (salbutamol). This version utilizes a low-carbon propellant, which could potentially reduce the greenhouse gas emissions from the associated metered dose inhaler (MDI) by…
-
Hunan Warrant Pharmaceutical’s ZG-001 Approved for Clinical Trial by NMPA
•
Hunan Warrant Pharmaceutical Co., Ltd (SHA: 688799), a China-based pharmaceutical company, has announced receiving clinical trial approval from the National Medical Products Administration (NMPA) for its Category 1 drug, ZG-001, intended to treat adults with major depressive disorder with acute suicidal ideation or behavior (MDSI). ZG-001’s Mechanism and Pre-Clinical Efficacy…
